Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan
研究概览
地位
条件
详细说明
Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.
Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.
The present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to pioglitazone in type 2 diabetic patients with uncontrolled blood glucose despite treatment with pioglitazone as well as diet and exercise therapies.
研究类型
注册 (实际的)
阶段
- 阶段2
- 第三阶段
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Had been taking pioglitazone at a stable dose (15 mg/day or 30 mg/day) for at least 16 weeks prior to the start of the treatment period (Week 0).
- Had glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 14 weeks after the start of the observation period (Week -2).
- Had HbA1c difference within 10.0%* at 10 weeks after the start of the observation period (Week -6) and 14 weeks after the start of the observation period (Week -2) from 10 weeks after the start of the observation period (Week -6) (*rounded off to the first decimal place).
- Was receiving specific diet and exercise (if any) therapies during the observation period.
Exclusion Criteria:
- Had taken a diabetic medications other than pioglitazone within 16 weeks before the start of the treatment period (Week 0).
- Had a history or symptoms of cardiac failure.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD
|
Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
其他名称:
Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
其他名称:
|
|
实验性的:Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD
|
Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
其他名称:
Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
其他名称:
|
|
有源比较器:Pioglitazone (15mg or 30mg ) QD
|
Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
糖基化血红蛋白相对于基线的变化(第 12 周)。
大体时间:基线和第 12 周。
|
第 12 周收集的糖化血红蛋白值(结合血红蛋白的葡萄糖浓度占可结合绝对最大值的百分比)和基线收集的糖化血红蛋白值的变化。
|
基线和第 12 周。
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
糖基化血红蛋白相对于基线的变化(第 8 周)。
大体时间:基线和第 8 周。
|
第 8 周收集的糖化血红蛋白值(结合血红蛋白的葡萄糖浓度占可结合绝对最大值的百分比)和基线收集的糖化血红蛋白值的变化。
|
基线和第 8 周。
|
|
糖基化血红蛋白相对于基线的变化(第 2 周)。
大体时间:基线和第 2 周。
|
第 2 周收集的糖化血红蛋白值(结合血红蛋白的葡萄糖浓度占可结合绝对最大值的百分比)和基线收集的糖化血红蛋白值的变化。
|
基线和第 2 周。
|
|
糖基化血红蛋白相对于基线的变化(第 4 周)。
大体时间:基线和第 4 周。
|
第 4 周收集的糖化血红蛋白值(结合血红蛋白的葡萄糖浓度占可结合绝对最大值的百分比)和基线收集的糖化血红蛋白值的变化。
|
基线和第 4 周。
|
|
Change From Baseline in Fasting Plasma Glucose (Week 2).
大体时间:Baseline and Week 2.
|
The change between the value of fasting plasma glucose collected at week 2 and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 2.
|
|
Change From Baseline in Fasting Plasma Glucose (Week 4).
大体时间:Baseline and Week 4.
|
The change between the value of fasting plasma glucose collected at week 4 and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 4.
|
|
Change From Baseline in Fasting Plasma Glucose (Week 8).
大体时间:Baseline and Week 8.
|
The change between the value of fasting plasma glucose collected at week 8 and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 8.
|
|
Change From Baseline in Fasting Plasma Glucose (Week 12).
大体时间:Baseline and Week 12.
|
The change between the value of fasting plasma glucose collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 12.
|
|
Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).
大体时间:Baseline and Week 12.
|
The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline.
Meal tolerance test measures blood glucose through blood samples drawn before a meal and 2 hours after the start of the meal.
|
Baseline and Week 12.
|
合作者和调查者
赞助
调查人员
- 研究主任:Professor, Diabetes and Endocrine Division, Department of Medicine、Kawasaki Medical School
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.